The pathomorphosis of inflammatory bowel diseases

Cover Page
  • Authors: Maev I.V.1, Shelygin Y.A.2, Skalinskaya M.I.3, Veselov A.V.2, Skazyvaeva E.V.3, Rasmagina I.A.3, Komarova D.A.3, Bakulin I.G.3
  • Affiliations:
    1. A.I. Yevdokimov Moscow State University of Medicine and Dentistry
    2. State research center of coloprotology named after A.N. Ryzhikh
    3. North-Western State Medical University n.a. I.I. Mechnikov
  • Issue: Vol 75, No 1 (2020)
  • Pages: 27-35
  • Section: INTERNAL DISEASES: CURRENT ISSUES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/1219
  • DOI: https://doi.org/10.15690/vramn1219
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Inflammatory bowel diseases (IBD) are immune-mediated diseases and usually manifest at a young age. They are requires in a long-term treatment or surgery with a high probability of surgical intervention. IBDs are accompanied by a decrease in working capacity, impaired quality of life and social disadaptation. However, timely diagnosis with using modern diagnostic methods, the use of evidence-based immunosuppressive and biological therapy significantly changed the pathomorphosis of this disease. But despite the achievements of the pharmacotherapy, the incidence and prevalence of IBD are still increasing, a demand for surgery remains both for Crohn`s disease and ulcerative colitis throughout all the period of illness. At the same time there is a trend towards the variability of symptoms, mismatch of the clinical symptoms with the real severity of inflammation, increase of a number of patients with extraintestinal manifestations and resistance to induction and maintenance therapies. In addition to this, the observation of this group of patients is complicated due to the difficulty of the early diagnosis and differential analysis of IBD, the need of early induction treatment according to the guidelines and the lack of adherence to the therapy.


Full Text

Restricted Access

About the authors

Igor V. Maev

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: igormaev@rambler.ru

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

MD, PhD, Professor

Yurii A. Shelygin

State research center of coloprotology named after A.N. Ryzhikh

Email: info@gnck.ru

Russian Federation, 2, Salyama Adilya street, Moscow, 123423

MD, PhD, Professor

Maria I. Skalinskaya

North-Western State Medical University n.a. I.I. Mechnikov

Author for correspondence.
Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0003-0769-8176
SPIN-code: 2596-5555

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

Associate Professor

Alexey V. Veselov

State research center of coloprotology named after A.N. Ryzhikh

Email: info@gnck.ru
ORCID iD: 0000-0002-2533-8118
SPIN-code: 9333-8673

Russian Federation, 2, Salyama Adilya street, Moscow, 123423

MD, PhD

Ekaterina V. Skazyvaeva

North-Western State Medical University n.a. I.I. Mechnikov

Email: skazyvaeva@yandex.ru
41, Kirochnaya street, Saint-Petersburg, 191015

MD, PhD

Irina A. Rasmagina

North-Western State Medical University n.a. I.I. Mechnikov

Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0003-3525-3289
SPIN-code: 6634-0342

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

resident in the specialty gastroenterology of the department of propaedeutics of internal diseases, gastroenterology and nutrition CM. Ryssa

Diana A. Komarova

North-Western State Medical University n.a. I.I. Mechnikov

Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0001-8834-0912
SPIN-code: 3599-4519

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

medical student

Igor G. Bakulin

North-Western State Medical University n.a. I.I. Mechnikov

Email: igbakulin@yandex.ru
ORCID iD: 0000-0002-6151-2021
SPIN-code: 5283-2032

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

MD, PhD, Professor

References

  1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769−2778. doi: 10.1016/S0140-6736(17)32448-0.
  2. Bernstein CN. Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology. Aliment Pharmacol Ther. 2017;46(10):911−919. doi: 10.1111/apt.14338.
  3. Ghersin I, Khteeb N, Katz LH, et al. Trends in the epidemiology of inflammatory bowel disease among jewish Israeli adolescents: a population-based study. Aliment Pharmacol Ther. 2019;49(5):556−563. doi: 10.1111/apt.15160.
  4. Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986−2015. J Crohns Colitis. 2019;13(11):1410−1417. doi: 10.1093/ecco-jcc/jjz081.
  5. Веселов А.В. Анализ данных медицинской статистики по вопросам оказания колопроктологической помощи населению города Москвы // Клинический опыт Двадцатки. ― 2014. ― №4. ― С. 26−29. [Veselov AV. Analiz dannykh meditsinskoi statistiki po voprosam okazaniia koloproktologicheskoi pomoshchi naseleniiu goroda Moskvy. Klinicheskii opyt Dvadtsatki. 2014;(4):26−29. (In Russ).]
  6. Биннатли Ш.А., Алешин Д.В., Куликов А.Э., и др. Качество жизни пациентов, оперированных по поводу язвенного колита (обзор литературы) // Колопроктология. ― 2019. ― Т.18. ― №1. ― С. 89−100. [Binnatli ShA, Aleshin DV, Kulikov AE, et al. Quality life of patients operated for ulcerative colitis. Koloproktologiia. 2019;18(1):89−100. (In Russ).]
  7. Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21(8):40−46. doi: 10.1007/s11894-019-0705-6.
  8. Веселов А.В., Кашников В.Н., Запольский А.Г. Состояние оказания колопроктологической помощи населению г. Москвы // Медицинские технологии. Оценка и выбор. ― 2014. ― №4. ― С. 29−33. [Veselov AV, Kashnikov VN, Zapol’skii AG. State of coloproctological care provision to the population of the city of Moscow. Meditsinskie tekhnologii. Otsenka i vybor. 2014;(4):29−33. (In Russ).]
  9. Шелыгин Ю.А, А.В. Веселов, Сербина А.А. Основные направления организации специализированной колопроктологической помощи // Колопроктология. ― 2017. ― №1. ― С. 76−81. [Shelygin YuA, Veselov AV, Serbina AA. Main directions of organization of a specialized coloproctological medical care. Koloproktologiia. 2017;(1):76−81. (In Russ).]
  10. Macdonald G. Harrison’s internal medicine, 17th edition. Int Med J. 2008;38:932–932. doi: 10.1111/j.1445-5994.2008.01837.
  11. Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterol. 2019;156(5):1345−1353.e4. doi: 10.1053/j.gastro.2019.01.002.
  12. Benchimol EI, Bernstein CN, Bitton A, et al. The impact of inflammatory bowel disease in Canada 2018: a scientific report from the Canadian gastro-intestinal epidemiology consortium to crohn’s and colitis Canada. J Canad Associat Gastroenterol. 2019;2(1):1–5. doi: 10.1093/jcag/gwy052.
  13. Bernstein CN, Nugent Z, Targownik LE, et al. Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut. 2015;64(9):1403−1411. doi: 10.1136/gutjnl-2014-307983.
  14. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflam Bowel Dis. 2013;19(4):789−799. doi: 10.1097/MIB.0b013e31828029c0.
  15. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., и др. Клинические рекомендации российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению язвенного колита // Колопроктология. ― 2017. ― №1. ― С. 6−30. [Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical guide of russian association of gastroenterology and russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologiia. 2017;(1):6−30. (In Russ).]
  16. Бакулин И.Г., Жигалова Т.Н., Латария Э.Л., и др. Опыт внедрения федерального регистра пациентов с воспалительными заболеваниями кишечника в Санкт-Петербурге // Фарматека. ― 2017. ― №S5. ― С. 56−59. [Bakulin IG, Zhigalova TN, Latariya EL, et al. Experience of introduction of the Federal Registry of patients with inflammatory bowel diseases in Saint Petersburg. Farmateka. 2017;(S5):56−59. (In Russ).]
  17. Осипенко М.Ф., Валуйских Е.Ю., Светлова И.О., и др. Регистр воспалительных заболеваний кишечника в г. Новосибирске: итоги-2016 // Сибирский научный медицинский журнал. ― 2017. ― Т.37. ― №1. ― С. 61−67. [Osipenko MF, Valuiskikh EYu, Svetlova IO, et al. Register of inflammatory bowel diseases in Novosibirsk-2016. Sibirskii nauchnyi meditsinskii zhurnal. 2017;37(1):61−67. (In Russ).]
  18. Everhov АH, Sachs MC, Malmborg P. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastr. 2019;54(1):55−63. doi: 10.1080/00365521.2018.1564361.
  19. Li X, Sundquist J, Hemminki K, et al. Risk of inflammatory bowel disease in first- and second-generation immigrants in Sweden: a nationwide follow-up study. Inflam Bowel Dis. 2011;17(8):1784−1791. doi: 10.1002/ibd.21535.
  20. Bernstein CN, Benchimol EI, Bitton A, et al. The impact of inflammatory bowel disease in Canada 2018: extra-intestinal diseases in IBD. J Canad Ass Gastr. 2019;2(1):73–80. doi: 10.1093/jcag/gwy053.
  21. Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obesity Facts. 2009;2(6):370−372. doi: 10.1159/000262276.
  22. Кашников В.Н., Михайлова Т.Л., Головенко О.В., и др. Тяжелая генерализованная форма гангренозной пиодермии у больной язвенным колитом (клиническое наблюдение) // Колопроктология. ― 2011. ― №1. ― С. 37−40. [Kashnikov VN, Mikhailova TL, Golovenko OV, et al. Tiazhelaia generalizovannaia forma gangrenoznoi piodermii u bol’noi iazvennym kolitom (klinicheskoe nabliudenie). Koloproktologiia. 2011;(1):37−40. (In Russ).]
  23. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastr. 2001;96(4):1116−1122. doi: 10.1111/j.1572-0241.2001.03756.x.
  24. Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort-an Epi-IBD study. J Crohn Colitis. 2019;13(2):198−208. doi: 10.1093/ecco-jcc/jjy154.
  25. Кашников В.Н. Хирургическая стратегия лечения больных язвенным колитом: Автореф. дис. … докт. мед. наук. ― М., 2017. ― 37 с. [Kashnikov VN. Khirurgicheskaia strategiia lecheniia bol’nykh iazvennym kolitom. [dissertation abstract] Moscow; 2017. 37 р. (In Russ).] Доступно по: https://search.rsl.ru/ru/record/01008710266. Ссылка активна на 14.11.2019.
  26. Candido FD, Fiorino G, Spadaccini M, et al. Are surgical rates decreasing in the biological era in IBD? Curr Drug Targets. 2019;20(13):1356−1362. doi: 10.2174/1389450120666190426165325.
  27. Viscido A, Papi C, Latella G, et al. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics. 2019;13:23–31. doi: 10.2147/BTT.S179006.
  28. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastr Hepatol. 2007;5(1):103−110. doi: 10.1016/j.cgh.2006.09.033.
  29. Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context. 2019;8:212572. doi: 10.7573/dic.212572.
  30. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979−2011. Gut. 2014;63(10):1607−1616. doi: 10.1136/gutjnl-2013-305607.
  31. Халиф И.Л., Шапина М.В., Головенко А.О., и др. Течение хронических воспалительных заболеваний кишечника и методы их лечения, применяемые в Российской Федерации (результаты многоцентрового популяционного одномоментного наблюдательного исследования) // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. ― 2018 ― Т.28. ― №3. ― С. 54−62. [Khalif IL, Shapina MV, Golovenko AO, et al. Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study). Russian Journal Gastroenterology, Hepatology, Coloproctology. 2018;28(3):54−62. (In Russ).]
  32. Manninen P, Karvonen AL, Laukkarinen J, et al. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease. Scand J Gastr. 2015;50(4):423−428. doi: 10.3109/00365521.2014.946085.
  33. Sokol H, Beaugerie L, Maynadié M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflam Bowel Disease. 2012;18(11):2063−2071. doi: 10.1002/ibd.22889.
  34. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526−535. doi: 10.1136/gut.48.4.526.
  35. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastr. 2005;100(12):2724−2729. doi: 10.1111/j.1572-0241.2005.00287.x.
  36. Biancone L, Armuzzi A, Scribano ML, et al. Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study. Inflam Bowel Dis. 2019;26(3):450−459. doi: 10.1093/ibd/izz155.
  37. Axelrad JE, Lichtiger S, Yajnik V.. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastr. 2016;22(20):4794−4801. doi: 10.3748/wjg.v22.i20.4794.
  38. Pasternak B, Svanström H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177(11):1296−1305. doi: 10.1093/aje/kws375.
  39. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63(9):1416−1423. doi: 10.1136/gutjnl-2013-305763.
  40. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. J Am Med Assoc. 2014;311(23):2406−2413. doi: 10.1001/jama.2014.5613.
  41. Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58−64. doi: 10.1016/j.cgh.2015.07.037.

Supplementary files

Supplementary Files Action
1.
Fig. 1. The distribution of the number of patients by year of primary diagnosis of ulcerative colitis or Crohn's disease

View (111KB) Indexing metadata
2.
Fig. 2. Dynamics of the frequency of primary diagnoses of inflammatory bowel diseases over 5-year periods with reflection of the shares of ulcerative colitis or Crohn's disease

View (72KB) Indexing metadata
3.
Fig. 3. The distribution of patients with ulcerative colitis according to the localization of the inflammatory process in the intestine

View (36KB) Indexing metadata
4.
Fig. 4. Distribution of patients with Crohn's disease by the frequency of detection of the localization of the lesion

View (33KB) Indexing metadata
5.
Fig. 5. The distribution of extraintestinal manifestations in patients with inflammatory bowel disease in groups

View (48KB) Indexing metadata
6.
Fig. 6. The nature of the performed surgical interventions to the patients of the Register during the medical history

View (81KB) Indexing metadata

Statistics

Views

Abstract - 503

PDF (Russian) - 2

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies